T
Thomas Powles
Researcher at Queen Mary University of London
Publications - 804
Citations - 57482
Thomas Powles is an academic researcher from Queen Mary University of London. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 82, co-authored 655 publications receiving 39271 citations. Previous affiliations of Thomas Powles include Charing Cross Hospital & University of London.
Papers
More filters
Journal ArticleDOI
Outcomes based on age in the phase III METEOR trial of cabozantinib versus everolimus in patients with advanced renal cell carcinoma
Frede Donskov,Robert J. Motzer,Eric Voog,Elizabeth Jane Hovey,Carsten Grüllich,Louise M. Nott,Katharine Cuff,Thierry Gil,Niels Viggo Jensen,Christine Chevreau,Sylvie Negrier,Reinhard Depenbusch,Lothar Bergmann,Izzy Cornelio,Anne Champsaur,Bernard Escudier,Sumanta K. Pal,Thomas Powles,Toni K. Choueiri +18 more
TL;DR: Cabozantinib improved PFS, OS and ORR compared with everolimus in previously treated patients with advanced RCC, irrespective of age group, supporting use in all age categories.
Journal ArticleDOI
Deferred Cytoreductive Nephrectomy Following Presurgical Vascular Endothelial Growth Factor Receptor–targeted Therapy in Patients with Primary Metastatic Clear Cell Renal Cell Carcinoma: A Pooled Analysis of Prospective Trial Data
Roderick de Bruijn,Akhila Wimalasingham,Bernadett Szabados,Grant D. Stewart,Sarah J. Welsh,Teele Kuusk,Christian U. Blank,John B. A. G. Haanen,Tobias Klatte,Tobias Klatte,Michael Staehler,Thomas Powles,Axel Bex,Axel Bex +13 more
TL;DR: In MSKCC intermediate-risk patients, a strategy of deferred CN in the absence of progression yields OS, which compares favourably with upfront CN and published trial data from CARMENA.
Journal ArticleDOI
A validated prognostic index predicting response to dexamethasone and diethylstilbestrol in castrate-resistant prostate cancer†
Jonathan Shamash,Justin Stebbing,Christopher Sweeney,Guru Sonpavde,Steve Harland,Guy Dawkins,Cathryn S Brock,Walter Abelman,Peter Wilson,Adam Sanitt,Tim Oliver,Thomas Powles +11 more
TL;DR: The objective of this study was to identify subgroups of patients with castrate‐resistant prostate cancer who had a prolonged response to combined dexamethasone and diethylstilbestrol therapy by constructing a prognostic index.
Journal ArticleDOI
First-line Nivolumab plus Ipilimumab Versus Sunitinib in Patients Without Nephrectomy and With an Evaluable Primary Renal Tumor in the CheckMate 214 Trial.
Zhijiang Wang,Laurence Albiges,Nizar M. Tannir,Mauricio Burotto,David F. McDermott,Elizabeth R. Plimack,Philippe Barthélémy,Camillo Porta,Thomas Powles,Frede Donskov,Saby George,Christian Kollmannsberger,Howard Gurney,Marc-Oliver Grimm,Yoshihiko Tomita,Daniel Castellano,Brian I. Rini,Toni K. Choueiri,David Leung,Shruti Shally Saggi,Chung Wei Lee,M. Brent McHenry,Robert J. Motzer +22 more
TL;DR: The CheckMate 214 trial as mentioned in this paper compared first-line nivolumab plus ipilimumab (NIVO+IPI) versus sunitinib in a subgroup of 108 patients with advanced renal cell carcinoma (aRCC) without prior nephrectomy and with an evaluable primary tumor, a population underrepresented in clinical trials.
Journal ArticleDOI
Loss of expression of the tumour suppressor gene AIMP3 predicts survival following radiotherapy in muscle-invasive bladder cancer
P. Gurung,Abhi Veerakumarasivam,Abhi Veerakumarasivam,Magali Williamson,Nicholas Counsell,James Douglas,Wei Shen Tan,Andrew Feber,Simon J. Crabb,Susan C Short,Alex Freeman,Thomas Powles,Peter Hoskin,Catharine M L West,John D. Kelly +14 more
TL;DR: AIMP3 expression is lost in a subset of bladder cancers and is significantly predictive of survival following radiotherapy in MIBC patients after radiotherapy, according to a meta‐analysis of a global gene‐expression dataset.